nRichDX

nRichDX nRichDX’s Revolution Sample Prep System: cfDNA, cfTNA from plasma or urine samples of 1-20 mL

“𝗜𝘁’𝘀 𝗮 𝘄𝗿𝗮𝗽.”AACR 2026.A week defined by meaningful data, real conversations, and a team pushing this space forward.Fiv...
04/23/2026

“𝗜𝘁’𝘀 𝗮 𝘄𝗿𝗮𝗽.”

AACR 2026.

A week defined by meaningful data, real conversations, and a team pushing this space forward.

Five posters across cfDNA, cfRNA, cfTNA, CTCs and high-throughput workflows.
The introduction of Revolution Pro.
One consistent theme across every discussion:

𝗪𝗵𝗮𝘁 𝗲𝗻𝘁𝗲𝗿𝘀 𝘁𝗵𝗲 𝗮𝘀𝘀𝗮𝘆 𝗱𝗲𝗳𝗶𝗻𝗲𝘀 𝘄𝗵𝗮𝘁 𝗰𝗮𝗻 𝗯𝗲 𝗱𝗲𝘁𝗲𝗰𝘁𝗲𝗱.

From early-stage conversations to a fully realized platform, this moment reflects both how far nRichDX has come and where it’s going.

To everyone who stopped by Booth #3345, thank you.
And to the team behind it all, this level of ex*****on doesn’t happen by accident.

That shift is already underway.





In this study, cfDNA was isolated using the nRichDX Revolution cfDNA Max 20 kit, and researchers demonstrated:• Strong c...
04/17/2026

In this study, cfDNA was isolated using the nRichDX Revolution cfDNA Max 20 kit, and researchers demonstrated:

• Strong correlation between cfDNA and whole blood DNA measurements (R² ≥ 0.9)
• Reliable detection of high VAF mutations in plasma
• The ability to support longitudinal monitoring when whole blood isn’t available
• This has real implications.

It expands what’s possible with existing sample types and reinforces a critical point:
What happens upstream directly impacts what can be measured downstream.

Read the publication: https://bit.ly/3OlpQ3O

Attending AACR 2026?
Visit Booth #3345 to see Revolution Pro in action and understand how high-recovery extraction can impact your workflow.





In this study, researchers conducted a comprehensive analytical validation of cfDNA extraction across multiple inputs, c...
04/16/2026

In this study, researchers conducted a comprehensive analytical validation of cfDNA extraction across multiple inputs, controls, and real-world conditions. Key findings include:

• Strong linearity and recovery across input ranges (R² ≥ 0.99)
• Consistent fragment size distribution with minimal genomic DNA contamination
• High reproducibility across operators and sample conditions
• Robust performance across variable pre-analytical environments

The study also leveraged nRichDX cfDNA reference standards as part of its validation framework, reinforcing the importance of standardized inputs in achieving reliable and reproducible extraction performance

Why this matters:

When analyte recovery is limited during extraction:
• Sensitivity is reduced before analysis begins
• Assays are forced into greater complexity
• Costs increase
• Turnaround times extend

This creates a downstream problem that is often misattributed to the assay itself.

The reality:

Extraction doesn’t just influence performance.
Extraction can define the upper limit of overall workflow performance.

Read the publication: https://bit.ly/3Qe6kXu

Attending AACR 2026?

Visit Booth #3345 to see Revolution Pro in action and understand how high-recovery extraction can impact your workflow.

More information about AACR on our landing page at https://lnkd.in/gRpTKqKy





Most liquid biopsy conversations focus on the assay.But the cost pressure starts earlier.In MCED and MRD testing, fixed ...
04/15/2026

Most liquid biopsy conversations focus on the assay.
But the cost pressure starts earlier.

In MCED and MRD testing, fixed reimbursement means margins are won or lost on assay COGs.

Yet many workflows are forced into increasing complexity:
• Larger panels
• Deeper sequencing
• More UMI usage
• Advanced error correction
• Longer turnaround times

Why?
Because analyte input is limited upstream.

What isn’t recovered during extraction never enters the assay.
And what doesn’t enter the assay must be compensated for downstream — at a cost.

At nRichDX, we’re focused on a different approach:
• Improve analyte recovery
• Simplify assay design
• Reduce costs (COGs)
• Shorten turnaround times

As we head into AACR 2026, we’ll be showcasing how optimized extraction can enable simpler, lower-cost, and more scalable assays for early-stage cancer detection and MRD.

📍Visit us at Booth #3345 to learn more about Revolution Pro
More information about AACR on our landing page at https://bit.ly/48xxuig





AACR 2026 is almost here.We’ll be introducing Revolution Pro — the next-generation system in the nRichDX Revolution Plat...
04/09/2026

AACR 2026 is almost here.

We’ll be introducing Revolution Pro — the next-generation system in the nRichDX Revolution Platform.

Built to scale high-recovery extraction, Revolution Pro is designed to:
• Processes 96 samples per shift
• Supports multiple sample types and variable input volumes (1–50 mL) in a single batch
• Automates yield-optimizing workflows for both cfDNA, cfRNA, cfTNA and CTCs

This isn’t just about automation.

It’s about increasing unique and diverse molecules — and what becomes possible downstream.

Join us at AACR to see Revolution Pro in action (Booth #3345).

If you’re working in liquid biopsy, this is worth a closer look.





03/21/2026

🐦 Ahh Spring...
Apparently even the local wildlife is trying to get their hands (beaks?) on our products.
Hate to break it to our feathered QA inspector—Our components aren’t on the menu.
No samples (or ravens) were harmed. The components, however, passed a *very rigorous* peck test.
It ended well. The raven scored a microfiber towel for its new nest. 😄

[video credit to nRicher Jason Autajay]

Spike-and-Recover cfDNA Reference StandardConfidence in liquid biopsy starts with consistent inputs. Variability can mas...
03/20/2026

Spike-and-Recover cfDNA Reference Standard
Confidence in liquid biopsy starts with consistent inputs. Variability can mask true performance and low-frequency variants.
The nRichDX cfDNA Reference Standard delivers reproducible, native-like cfDNA in a convenient thaw-and-use format—enabling accurate assessment of extraction, library prep, and downstream assay sensitivity, even for low-input samples. More info: https://bit.ly/4sQk3Sq

03/05/2026

Stage I detection isn’t just an assay challenge—it’s an extraction challenge.
nRichDX's extraction platform enables Stage 1 detection.

With low analyte concentration, urine requires more sample volume. nRichDX processes up to 50 mL in a single extraction,...
02/24/2026

With low analyte concentration, urine requires more sample volume. nRichDX processes up to 50 mL in a single extraction, enabling higher analyte recovery for early cancer and MRD detection.

Two posters. One white paper. Real Data. Let's Talk. See links in comment below.

02/10/2026

MCED and MRD assays continue to evolve, yet early detection often hinges on a single factor: nucleic acid extraction. Higher analyte yield drives greater sensitivity—and earlier insight into rare cancer markers.

See how improved extraction can elevate your assay. Learn more at the link in the comment below.

Address

15339 Barranca Pkwy
Irvine, CA
92618

Telephone

+19493411980

Website

Alerts

Be the first to know and let us send you an email when nRichDX posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category